LncRNA XIST Promotes Human Lung Adenocarcinoma Cells to Cisplatin Resistance Via Let-7i/BAG-1 Axis

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2017 Sep 30

PMID 28961027

Citations 44

Authors

Jing Sun

Li-Ming Pan

Li-Bo Chen

Yue Wang

Affiliations

Soon will be listed here.

Abstract

Long noncoding RNAs (lncRNAs) have been identified as oncogenes or tumor suppressors that are involved in tumorigenesis and chemoresistance. LncRNA XIST expression is upregulated in several cancers, however, its biologic role in the development of the chemotherapy of human lung adenocarcinoma (LAD) has not been elucidated. This study aimed to observe the expression of LncRNA XIST in LAD and to evaluate its biologic role and clinical significance in the resistance of LAD cells to cisplatin. LncRNA XIST expression was markedly increased in cisplatin-resistant A549/DDP cells compared with parental A549 cells as shown by qRT-PCR. LncRNA XIST overexpression in A549 cells increased their chemosensitivity to cisplatin both in vitro and in vivo by protecting cells from apoptosis and promoting cell proliferation. By contrast, LncRNA XIST knockdown in A549/DDP cells decreased the chemoresistance. We revealed that XIST functioned as competing endogenous RNA to repress let-7i, which controlled its down-stream target BAG-1. We proposed that XIST was responsible for cisplatin resistance of LAD cells and XIST exerted its function through the let-7i/BAG-1 axis. Our findings suggested that lncRNA XIST may be a new marker of poor response to cisplatin and could be a potential therapeutic target for LAD chemotherapy.

Citing Articles

GATA1 activates HSD17B6 to improve efficiency of cisplatin in lung adenocarcinoma via DNA damage.

Shao X, Hou H, Chen H, Xia W, Geng X, Wang J Genes Environ. 2024; 46(1):27.

PMID: 39695810 PMC: 11654308. DOI: 10.1186/s41021-024-00321-9.

A review of the complex interplay between chemoresistance and lncRNAs in lung cancer.

Alnefaie G J Transl Med. 2024; 22(1):1109.

PMID: 39639388 PMC: 11619437. DOI: 10.1186/s12967-024-05877-2.

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.

Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.

PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.

"Crosstalk between non-coding RNAs and transcription factor LRF in non-small cell lung cancer".

Spella M, Bochalis E, Athanasopoulou K, Chroni A, Dereki I, Ntaliarda G Noncoding RNA Res. 2024; 9(3):759-771.

PMID: 38577020 PMC: 10990748. DOI: 10.1016/j.ncrna.2024.03.009.

Long non-coding RNA and Evolving drug resistance in lung cancer.

Wang M, Fu Y, Zhong C, Gacche R, Wu P Heliyon. 2023; 9(12):e22591.

PMID: 38089985 PMC: 10711135. DOI: 10.1016/j.heliyon.2023.e22591.

References

Fawzy I, Hamza M, Hosny K, Esmat G, Abdelaziz A . Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. Growth Factors. 2016; 34(1-2):42-50. DOI: 10.3109/08977194.2016.1169532. View

Yang L, McBurney D, Tang S, Carlson S, Horton Jr W . A novel role for Bcl-2 associated-athanogene-1 (Bag-1) in regulation of the endoplasmic reticulum stress response in mammalian chondrocytes. J Cell Biochem. 2007; 102(3):786-800. DOI: 10.1002/jcb.21328. View

Huang K, Rao P, Lau C, Heard E, Ng S, Brown C . Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002; 1(10):769-76. View

Gregory R, Chendrimada T, Cooch N, Shiekhattar R . Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005; 123(4):631-40. DOI: 10.1016/j.cell.2005.10.022. View

Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K . MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008; 68(24):10307-14. PMC: 2762326. DOI: 10.1158/0008-5472.CAN-08-1954. View

Greenhough J, Papadakis E, Cutress R, Townsend P, Oreffo R, Tare R . Regulation of osteoblast development by Bcl-2-associated athanogene-1 (BAG-1). Sci Rep. 2016; 6:33504. PMC: 5025845. DOI: 10.1038/srep33504. View

Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan J . Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 1995; 80(2):279-84. DOI: 10.1016/0092-8674(95)90410-7. View

Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H . Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget. 2016; 7(22):32433-48. PMC: 5078024. DOI: 10.18632/oncotarget.8653. View

Chen Q, Wei C, Wang Z, Sun M . Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 2016; 8(1):1925-1936. PMC: 5352108. DOI: 10.18632/oncotarget.12461. View

10.

Wang H, Shen Q, Zhang X, Yang C, Cui S, Sun Y . The Long Non-Coding RNA XIST Controls Non-Small Cell Lung Cancer Proliferation and Invasion by Modulating miR-186-5p. Cell Physiol Biochem. 2017; 41(6):2221-2229. DOI: 10.1159/000475637. View

11.

Karginov F, Conaco C, Xuan Z, Schmidt B, Parker J, Mandel G . A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A. 2007; 104(49):19291-6. PMC: 2148283. DOI: 10.1073/pnas.0709971104. View

12.

Brown C, Ballabio A, Rupert J, Lafreniere R, Grompe M, Tonlorenzi R . A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. 1991; 349(6304):38-44. DOI: 10.1038/349038a0. View

13.

Liu H, Lu S, Gu L, Gao Y, Wang T, Zhao J . Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen. Cell Physiol Biochem. 2014; 33(2):365-74. DOI: 10.1159/000356676. View

14.

Tantai J, Hu D, Yang Y, Geng J . Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Int J Clin Exp Pathol. 2015; 8(7):7887-95. PMC: 4555681. View

15.

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A . Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014; 5:e1257. PMC: 4047912. DOI: 10.1038/cddis.2013.428. View

16.

Chang A . Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2010; 71(1):3-10. DOI: 10.1016/j.lungcan.2010.08.022. View

17.

Devesa S, Bray F, Vizcaino A, Parkin D . International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005; 117(2):294-9. DOI: 10.1002/ijc.21183. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

19.

Godinho M, Meijer D, Setyono-Han B, Dorssers L, van Agthoven T . Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol. 2011; 226(7):1741-9. DOI: 10.1002/jcp.22503. View

20.

Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P . The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma. PLoS One. 2015; 10(5):e0114586. PMC: 4439130. DOI: 10.1371/journal.pone.0114586. View